Nutriband Develops Innovative Abuse-Deterrent Transdermal Drug Technology

Nutriband Inc., a pharmaceutical development company, is advancing innovative transdermal drug technology designed to improve medication safety and reduce potential drug abuse. The company's AVERSA™ technology represents a significant breakthrough in developing abuse-deterrent pharmaceutical patches.

The technology offers a comprehensive approach to preventing drug misuse, diversion, and accidental exposure, particularly for high-risk medications like fentanyl. With patents secured in multiple countries including the United States, Europe, Japan, and China, Nutriband's solution addresses a critical challenge in pharmaceutical development.

The company's strategic business model focuses on applying its transdermal technology to existing FDA-approved drugs. By doing so, Nutriband aims to enhance medication safety, improve patient comfort, and leverage a regulatory pathway that reduces clinical trial requirements for new drug approvals.

AVERSA technology's potential impact extends beyond individual product development. It represents a potential paradigm shift in pharmaceutical safety, offering a mechanism to mitigate the risks associated with drugs susceptible to abuse while maintaining therapeutic accessibility for patients who genuinely need these medications.

Nutriband's lead product, an abuse-deterrent fentanyl patch incorporating AVERSA technology, demonstrates the practical application of this innovative approach. The technology can be integrated into various transdermal patches, presenting a versatile solution for pharmaceutical manufacturers concerned with medication safety.